LGMD 2D gene therapy receives Orphan Drug Designation

Published Date
Beatriz Bustillo Ramirez
Orange box stating: Breaking news research

Myonexus Therapeutics’ gene therapy for limb girdle muscular dystrophy type 2D, MYO-102, has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA). This gives Myonexus certain benefits that will help with the development of MYO-102.

For further information, please read Myonexus’ press release.

If you have any questions about this news story or any other LGMD research, please contact the MDUK Research Line on 020 7803 4813 or email research@musculardystrophyuk.org.

Keep in touch